目前尚无根治重症肌无力的特效药，且该病因分型多样、受病人群多样，故其治疗选择也不 同，长短期疗效、预后及安全性也存在差异。为给患者选择安全有效的用药方案，本文将结合中外相关研 究，对 2020 年中国免疫学会和美国重症肌无力基金会发布的重症肌无力最新指南，进行对比分析，并对重 症肌无力常用治疗进行阐述，旨在为临床医生提供更多参考。

At present，there is no specific drug for the radical treatment of myasthenia gravis. The thera⁃ pies vary with different etiology and population of patients as well，with discrepancies in long⁃term and short⁃term efficacy，prognosis and safety. In order to select a safe and effective medication regimen for the patients，this paper reviews the relevant domestic and foreign studies and compares the latest guidelines of myasthenia gravis issued by the Chinese Society for Immunology and the Myasthenia Gravis Foundation of America in 2020，aiming to provide surgeons with more references for the treatment of myasthenia gravis.